Beyond Is Maintained at Equal-Weight by Barclays
Beyond Analyst Ratings
Barclays Maintains Beyond(BYON.US) With Hold Rating, Maintains Target Price $7
Barclays Maintains Beyond(BYON.US) With Hold Rating, Cuts Target Price to $7
Beyond Cut to Sell From Hold by Argus Research
Argus Research Downgrades Beyond(BYON.US) to Sell Rating
Beyond Analyst Ratings
Piper Sandler Releases a Buy Rating on Beyond Air (XAIR)
Beyond Meat Faces Revenue and Financing Challenges Amid Persistent Risks, Analyst Recommends Sell
Cautious Stance on Beyond Meat: Sell Rating Due to Uncertain Path to Profitability
Barclays Remains a Sell on Beyond Meat (BYND)
Beyond Price Target Cut to $8.00/Share From $14.00 by Barclays
Beyond Is Maintained at Equal-Weight by Barclays
Beyond Analyst Ratings
Barclays Maintains Beyond(BYON.US) With Hold Rating, Cuts Target Price to $8
Biogen's Strategic Shift: Felzartamab's Promise in IgAN and Beyond Fuels Buy Rating
BTIG Maintains Beyond(BYON.US) With Hold Rating
Maxim Group Maintains Beyond(BYON.US) With Buy Rating
Tom Forte Maintains Buy Rating on Beyond Despite Weak Q3 Results, Citing Strategic Vision and Financial Resilience
Beyond Is Maintained at Buy by Maxim Group